349 related articles for article (PubMed ID: 27683758)
1. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.
Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW
Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758
[TBL] [Abstract][Full Text] [Related]
2. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
Front Immunol; 2020; 11():1293. PubMed ID: 32670285
[TBL] [Abstract][Full Text] [Related]
3. Induction of tolerance to factor VIII by transient co-administration with rapamycin.
Moghimi B; Sack BK; Nayak S; Markusic DM; Mah CS; Herzog RW
J Thromb Haemost; 2011 Aug; 9(8):1524-33. PubMed ID: 21585650
[TBL] [Abstract][Full Text] [Related]
4. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice.
Zhang AH; Skupsky J; Scott DW
Blood; 2011 Feb; 117(7):2223-6. PubMed ID: 21160036
[TBL] [Abstract][Full Text] [Related]
5. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII.
Liu CL; Ye P; Lin J; Djukovic D; Miao CH
J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505
[TBL] [Abstract][Full Text] [Related]
6. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
[TBL] [Abstract][Full Text] [Related]
7. Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice.
Ramakrishnan R; Davidowitz A; Balu-Iyer SV
J Pharm Sci; 2015 Aug; 104(8):2451-6. PubMed ID: 26038127
[TBL] [Abstract][Full Text] [Related]
8. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
[TBL] [Abstract][Full Text] [Related]
9. B cell-activating factor modulates the factor VIII immune response in hemophilia A.
Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for treatment of inhibitors in haemophilia A. A Phase II study.
Leissinger C; Josephson CD; Granger S; Konkle BA; Kruse-Jarres R; Ragni MV; Journeycake JM; Valentino L; Key NS; Gill JC; McCrae KR; Neufeld EJ; Manno C; Raffini L; Saxena K; Torres M; Marder V; Bennett CM; Assmann SF
Thromb Haemost; 2014 Sep; 112(3):445-58. PubMed ID: 24919980
[TBL] [Abstract][Full Text] [Related]
11. Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation.
Zhang AH; Rossi RJ; Yoon J; Wang H; Scott DW
Cell Immunol; 2016 Mar; 301():74-81. PubMed ID: 26687613
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
Field JJ; Fenske TS; Blinder MA
Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice.
Qadura M; Waters B; Burnett E; Chegeni R; Hough C; Othman M; Lillicrap D
Haemophilia; 2011 Mar; 17(2):288-95. PubMed ID: 21091850
[TBL] [Abstract][Full Text] [Related]
14. The humoral response to human factor VIII in hemophilia A mice.
Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P
J Thromb Haemost; 2007 Mar; 5(3):512-9. PubMed ID: 17181826
[TBL] [Abstract][Full Text] [Related]
15. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
16. Neutralisation of factor VIII inhibitors by anti-idiotypes isolated from phage-displayed libraries.
Schmidt A; Brettschneider K; Kahle J; Orlowski A; Becker-Peters K; Stichel D; Schulze J; Braner M; Tampé R; Schwabe D; Königs C
Thromb Haemost; 2016 Jul; 116(1):32-41. PubMed ID: 27009573
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
Carcao M; St Louis J; Poon MC; Grunebaum E; Lacroix S; Stain AM; Blanchette VS; Rivard GE;
Haemophilia; 2006 Jan; 12(1):7-18. PubMed ID: 16409170
[TBL] [Abstract][Full Text] [Related]
18. Immune tolerance induction in patients with hemophilia A.
Astermark J
Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
[TBL] [Abstract][Full Text] [Related]
19. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
20. O-phospho-l-serine mediates hyporesponsiveness toward FVIII in hemophilia A-murine model by inducing tolerogenic properties in dendritic cells.
Fathallah AM; Ramakrishnan R; Balu-Iyer SV
J Pharm Sci; 2014 Nov; 103(11):3457-3463. PubMed ID: 25266204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
